Effect of Semaglutide versus placebo on psychotic symptoms and quality of life - a pre-specified secondary analysis of HISTORI: A randomized clinical trial in people with pre-diabetes and schizophrenia
Introduction Life expectancy of people with schizophrenia is reduced by 10-20 years compared to the general population. The excess mortality is part due to an increased prevalence of cardiovascular disease, prediabetes and obesity, which are in part due to antipsychotic treatment. Gaining weight is...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2022-06-01
|
| Series: | European Psychiatry |
| Subjects: | |
| Online Access: | https://www.cambridge.org/core/product/identifier/S0924933822020648/type/journal_article |
| _version_ | 1797616145452236800 |
|---|---|
| author | N. Uhrenholt A. Ganeshalingam S. Arnfred J. Frystyk P. Gæde N. Bilenberg |
| author_facet | N. Uhrenholt A. Ganeshalingam S. Arnfred J. Frystyk P. Gæde N. Bilenberg |
| author_sort | N. Uhrenholt |
| collection | DOAJ |
| description |
Introduction
Life expectancy of people with schizophrenia is reduced by 10-20 years compared to the general population. The excess mortality is part due to an increased prevalence of cardiovascular disease, prediabetes and obesity, which are in part due to antipsychotic treatment. Gaining weight is associated with reduced quality of life and also among the most frequently reported reasons for the discontinuation of treatment. Lifestyle changes have a time limited effect, and therefore, interest has focused on Glucagon-Like Peptide 1 receptor agonist treatment. Semaglutide, currently used to treat type 2-diabetes in doses up to 1.0 mg once-weekly, has shown promising results regarding weight loss in doses up to 2.4 mg once-weekly. It may also be able to reduce the risk of developing diabetes and cardiovascular disease.
Objectives
The HISTORI Trial aims to reduce risk of developing diabetes and cardiovascular disease in people with schizophrenia, prediabetes and overweight and to investigate for an indirect effect of Semaglutide on psychotic symptoms and quality of life through a weight loss.
Methods
A 30 weeks randomized, placebo-controlled, double-blinded study with once-weekly injections of Semaglutide 1.0 mg. Primary inclusion criteria are age 18-40 years, schizophrenia, prediabetes, overweight and treatment with antipsychotics. Questionnaires and interviews regarding psychotic symptoms, quality of life, medication adherence and physical activity will be applied either monthly or every third month.
Results
will not be ready for the congress. A poster outlining the feasibility challenges will be presented.
Conclusions
Perspective: Through weight loss, Semaglutide may indirectly be able to improve quality of life, medication adherence and psychotic symptoms.
Disclosure
No significant relationships.
|
| first_indexed | 2024-03-11T07:37:13Z |
| format | Article |
| id | doaj.art-9aa25814565c4b57866ecc6baf8719df |
| institution | Directory Open Access Journal |
| issn | 0924-9338 1778-3585 |
| language | English |
| last_indexed | 2024-03-11T07:37:13Z |
| publishDate | 2022-06-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| series | European Psychiatry |
| spelling | doaj.art-9aa25814565c4b57866ecc6baf8719df2023-11-17T05:09:24ZengCambridge University PressEuropean Psychiatry0924-93381778-35852022-06-0165S798S79910.1192/j.eurpsy.2022.2064Effect of Semaglutide versus placebo on psychotic symptoms and quality of life - a pre-specified secondary analysis of HISTORI: A randomized clinical trial in people with pre-diabetes and schizophreniaN. Uhrenholt0A. Ganeshalingam1S. Arnfred2J. Frystyk3P. Gæde4N. Bilenberg5Psychiatry West, Region Zealand, Research Unit For Psychotherapy And Psychopathology, Slagelse, DenmarkOdense University Hospital., Department Of Endocrinology M / Steno Diabetes Centre Odense (sdco), Odense, DenmarkPsychiatry West, Region Zealand, Research Unit For Psychotherapy And Psychopathology, Slagelse, DenmarkOdense University Hospital., Department Of Endocrinology M / Steno Diabetes Centre Odense (sdco), Odense, DenmarkNæstved, Slagelse og Ringsted Hospital, Department Of Cardiology And Endocrinology, Slagelse, DenmarkMental Health Services in the Region of Southern Denmark, Child And Adolescent Psychiatry Odense, Odense C, Denmark Introduction Life expectancy of people with schizophrenia is reduced by 10-20 years compared to the general population. The excess mortality is part due to an increased prevalence of cardiovascular disease, prediabetes and obesity, which are in part due to antipsychotic treatment. Gaining weight is associated with reduced quality of life and also among the most frequently reported reasons for the discontinuation of treatment. Lifestyle changes have a time limited effect, and therefore, interest has focused on Glucagon-Like Peptide 1 receptor agonist treatment. Semaglutide, currently used to treat type 2-diabetes in doses up to 1.0 mg once-weekly, has shown promising results regarding weight loss in doses up to 2.4 mg once-weekly. It may also be able to reduce the risk of developing diabetes and cardiovascular disease. Objectives The HISTORI Trial aims to reduce risk of developing diabetes and cardiovascular disease in people with schizophrenia, prediabetes and overweight and to investigate for an indirect effect of Semaglutide on psychotic symptoms and quality of life through a weight loss. Methods A 30 weeks randomized, placebo-controlled, double-blinded study with once-weekly injections of Semaglutide 1.0 mg. Primary inclusion criteria are age 18-40 years, schizophrenia, prediabetes, overweight and treatment with antipsychotics. Questionnaires and interviews regarding psychotic symptoms, quality of life, medication adherence and physical activity will be applied either monthly or every third month. Results will not be ready for the congress. A poster outlining the feasibility challenges will be presented. Conclusions Perspective: Through weight loss, Semaglutide may indirectly be able to improve quality of life, medication adherence and psychotic symptoms. Disclosure No significant relationships. https://www.cambridge.org/core/product/identifier/S0924933822020648/type/journal_articleschizophréniaPrediabetesGlucagon-Like Peptide 1Positive and negative symptoms (PANSS) |
| spellingShingle | N. Uhrenholt A. Ganeshalingam S. Arnfred J. Frystyk P. Gæde N. Bilenberg Effect of Semaglutide versus placebo on psychotic symptoms and quality of life - a pre-specified secondary analysis of HISTORI: A randomized clinical trial in people with pre-diabetes and schizophrenia European Psychiatry schizophrénia Prediabetes Glucagon-Like Peptide 1 Positive and negative symptoms (PANSS) |
| title | Effect of Semaglutide versus placebo on psychotic symptoms and quality of life - a pre-specified secondary analysis of HISTORI: A randomized clinical trial in people with pre-diabetes and schizophrenia |
| title_full | Effect of Semaglutide versus placebo on psychotic symptoms and quality of life - a pre-specified secondary analysis of HISTORI: A randomized clinical trial in people with pre-diabetes and schizophrenia |
| title_fullStr | Effect of Semaglutide versus placebo on psychotic symptoms and quality of life - a pre-specified secondary analysis of HISTORI: A randomized clinical trial in people with pre-diabetes and schizophrenia |
| title_full_unstemmed | Effect of Semaglutide versus placebo on psychotic symptoms and quality of life - a pre-specified secondary analysis of HISTORI: A randomized clinical trial in people with pre-diabetes and schizophrenia |
| title_short | Effect of Semaglutide versus placebo on psychotic symptoms and quality of life - a pre-specified secondary analysis of HISTORI: A randomized clinical trial in people with pre-diabetes and schizophrenia |
| title_sort | effect of semaglutide versus placebo on psychotic symptoms and quality of life a pre specified secondary analysis of histori a randomized clinical trial in people with pre diabetes and schizophrenia |
| topic | schizophrénia Prediabetes Glucagon-Like Peptide 1 Positive and negative symptoms (PANSS) |
| url | https://www.cambridge.org/core/product/identifier/S0924933822020648/type/journal_article |
| work_keys_str_mv | AT nuhrenholt effectofsemaglutideversusplaceboonpsychoticsymptomsandqualityoflifeaprespecifiedsecondaryanalysisofhistoriarandomizedclinicaltrialinpeoplewithprediabetesandschizophrenia AT aganeshalingam effectofsemaglutideversusplaceboonpsychoticsymptomsandqualityoflifeaprespecifiedsecondaryanalysisofhistoriarandomizedclinicaltrialinpeoplewithprediabetesandschizophrenia AT sarnfred effectofsemaglutideversusplaceboonpsychoticsymptomsandqualityoflifeaprespecifiedsecondaryanalysisofhistoriarandomizedclinicaltrialinpeoplewithprediabetesandschizophrenia AT jfrystyk effectofsemaglutideversusplaceboonpsychoticsymptomsandqualityoflifeaprespecifiedsecondaryanalysisofhistoriarandomizedclinicaltrialinpeoplewithprediabetesandschizophrenia AT pgæde effectofsemaglutideversusplaceboonpsychoticsymptomsandqualityoflifeaprespecifiedsecondaryanalysisofhistoriarandomizedclinicaltrialinpeoplewithprediabetesandschizophrenia AT nbilenberg effectofsemaglutideversusplaceboonpsychoticsymptomsandqualityoflifeaprespecifiedsecondaryanalysisofhistoriarandomizedclinicaltrialinpeoplewithprediabetesandschizophrenia |